By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Topica Pharmaceuticals 

435 Tasso Street
Suite 325
Palo Alto  California  94301  U.S.A.
Phone: 650-473-3800 Fax: 650-473-3805



Company News
Topica Pharmaceuticals Announces 10% Luliconazole Program Ready For Phase 3 Development For Onychomycosis Based On Positive Phase 2 Results 9/16/2015 11:23:41 AM
Topica Pharmaceuticals Presents Interim Safety and Mycologic Results From Its Phase 2b/3 Onychomycosis Trial of 10% Luliconazole Solution at the Interscience Conference on Antimicrobial Agents and Chemotherapy 9/11/2013 9:29:03 AM
Topica Pharmaceuticals Presents Findings From Phase 1/2 Trial of Luliconazole Solution, 10% in Onychomycosis at ICAAC 2012 9/14/2012 9:05:39 AM
Topica Pharmaceuticals Initiates Phase 2b/3 Study of Luliconazole in Patients With Onychomycosis of the Toenails 6/27/2012 9:05:21 AM
Topica Pharmaceuticals Presents Promising Luliconazole Solution, 10% Data in Onychomycosis at 2012 American Academy of Dermatology Annual Meeting 3/19/2012 8:41:40 AM
Topica Pharmaceuticals Names Dr. Amir Tavakkol Senior Vice President of Clinical Development and Operations 12/5/2011 9:07:29 AM
Geron Corporation (GERN): A Tribute to Alex Barkas 11/23/2011 10:06:47 AM
Topica Pharmaceuticals Announces Completion of $27 Million Series B Financing 10/18/2011 6:52:48 AM
Topica Pharmaceuticals Announces Positive Results From Phase 1/2a Trial of Luliconazole for Treatment of Onychomycosis 6/20/2011 10:10:50 AM
Topica Pharmaceuticals Announces Appointment of David E. Cohen, M.D., to Board of Directors 3/28/2011 9:31:13 AM